Rachel M. Morris

Immune biomarkers for head and neck cancer

Navid Sobhani, Alberto D’Angelo, Fernanda Grande Kugeratski, Tristan Nguyen et autres

In recent years, head and neck cancer therapy has been revolutionized by immunotherapy, which aims to restore the immune system's anticancer activity suppressed by cancer cells. The major concern is that only a subset of patients responds to this therapy. Having specific …

us, gb, it (code pays fourni par la source)

Abstract PR-10: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade

Oluwatoyosi Adewunmi, Arielle G. Dessens, Aloukick Kumar Singh, Ashley Sunderland et autres

Abstract CD8 T cells are effector cells of the adaptive immune system responsible for mediating protective immune responses in cancer. However, CD8 T cells can also be critical drivers of pathologic responses including autoimmunity. A key feature of these cells is that …

us (code pays fourni par la source)

Abstract B001: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade

Oluwatoyosi Adewunmi, Arielle G. Dessens, Aloukick Kumar Singh, Ashley Sunderland et autres

Abstract CD8 T cells are effector cells of the adaptive immune system responsible for mediating protective immune responses in cancer. However, CD8 T cells can also be critical drivers of pathologic responses including autoimmunity. A key feature of these cells is that …

us (code pays fourni par la source)

Artificial intelligence-powered discovery of small molecules inhibiting CTLA-4 in cancer

Navid Sobhani, Dana Rae Tardiel-Cyril, Dafei Chai, Daniele Generali et autres

BACKGROUND/OBJECTIVES: Checkpoint inhibitors, which generate durable responses in many cancer patients, have revolutionized cancer immunotherapy. However, their therapeutic efficacy is limited, and immune-related adverse events are severe, especially for monoclonal antibody treatment directed against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which plays a …

us, it (code pays fourni par la source)

TK1 expression influences pathogenicity by cell cycle progression, cellular migration, and cellular survival in HCC 1806 breast cancer cells

Eliza E. Bitter, Jonathan R. Skidmore, Carolyn I. Allen, Rachel I. Erickson et autres

Breast cancer is the most common cancer diagnosis worldwide accounting for 1 out of every 8 cancer diagnoses. The elevated expression of Thymidine Kinase 1 (TK1) is associated with more aggressive tumor grades, including breast cancer. Recent studies indicate that TK1 may …

us (code pays fourni par la source)

233 Repolarizing M2 to M1 macrophages using chimeric antigen receptors (CAR) for solid tumors

Michael Joseph Boyer, Michelle H. Townsend, Timothy W. Phares, Adam G. Blaszczak et autres

Background Tumor associated macrophages (TAM) have been found to exert a number of pro-tumorigenic including suppression of immune effectors. These properties have been largely associated with an M2 phenotype, while an M1 phenotype has anti-tumor effects. We therefore screened CAR constructs for …

Artificial Intelligence-Powered Discovery of Small Molecules Inhibiting CTLA-4 in Cancer

Navid Sobhani, Dana Rae Tardiel-Cyril, Dafei Chai, Daniele Generali et autres

Abstract Checkpoint inhibitors, which generate durable responses in many cancer patients, have revolutionized cancer immunotherapy. However, their therapeutic efficacy is limited, and immune-related adverse events are very sever, especially for monoclonal antibody treatment directed against cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), which plays …

us, it (code pays fourni par la source)

The power of whole genomic sequencing in biomedical research and clinical applications

Navid Sobhani, Alberto D’Angelo, Felipe Umpierre Conter, Rachel M. Morris et autres

us, gb, br (code pays fourni par la source)

Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials

Navid Sobhani, Bruna Scaggiante, Rachel M. Morris, Dafei Chai et autres

us, it, cn, gb (code pays fourni par la source)

Abstract 159: Thymidine kinase 1 and cell cycle control in breast cancer

Eliza E. Bitter, Toni O. Mortimer, Rachel M. Morris, Kai Barlow et autres

Abstract Recent advances in cancer immunotherapy have transformed biomarkers into diagnostic and prognostic indicators and immunotherapeutic targets in clinical oncology. To ensure higher treatment success, it is critical to identify unique biomarkers to mitigate “off-target” effects. Therefore, the identification of novel biomarkers …

us (code pays fourni par la source)

Abstract 1322: The potential effects of thymidine kinase 1 on breast cancer invasion

Eliza E. Bitter, Rachel M. Morris, Toni O. Mortimer, Kai Barlow et autres

Abstract Breast cancer is the most common cancer in women and is largely treatable within the early stages of the disease. However, patient mortality drastically declines as the tumor begins to invade other tissues and metastasize, making aggressive phenotypes especially problematic to …

us (code pays fourni par la source)

Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer

Navid Sobhani, Richard Chahwan, Raheleh Roudi, Rachel M. Morris et autres

For decades since the central dogma, cancer biology research has been focusing on the involvement of genes encoding proteins. It has been not until more recent times that a new molecular class has been discovered, named non-coding RNA (ncRNA), which has been …

us, ch, it, gb (code pays fourni par la source)